Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands

Ellen H.M. Moors; Piret Kukk Fischer; Wouter P.C. Boon; Frank Schellen; Simona O. Negro

doi:10.1016/j.techfore.2017.11.011

Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands

Ellen H.M. Moors
, Piret Kukk Fischer
, Wouter P.C. Boon
, Frank Schellen
, Simona O. Negro

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Abstract The article aims to understand the institutionalisation process of markets for innovative products. To pursue this study of market formation, we analysed the introduction of innovative personalised medicines products: Herceptin® (trastuzumab) for breast cancer and Tarceva® (erlotinib) for lung cancer, which were introduced successively in the Netherlands between 2000 and 2012. We apply the technological innovation system (TIS) approach to understand the development, implementation and diffusion of new markets, including new roles for users and producers, new forms of regulation and novel user practices regarding innovative health technologies. We show that market access became institutionalised as part of the technological innovation system of the first-mover personalised medicine, i.e. the market was formed, paving the way for the later personalised medicine products.

Original language	English
Pages (from-to)	133-143
Journal	Technological Forecasting and Social Change
Volume	128
DOIs	https://doi.org/10.1016/j.techfore.2017.11.011
Publication status	Published - Mar 2018

Keywords

Market formation
Institutionalisation
Technological innovation system
Transition
Personalised cancer medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.techfore.2017.11.011

InstitutionalisationFinal published version, 312 KB

https://www.sciencedirect.com/science/article/pii/S0040162517315652

Cite this

@article{c1d4241cff54410aacf3028e655c5d1a,

title = "Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands",

abstract = "Abstract The article aims to understand the institutionalisation process of markets for innovative products. To pursue this study of market formation, we analysed the introduction of innovative personalised medicines products: Herceptin{\textregistered} (trastuzumab) for breast cancer and Tarceva{\textregistered} (erlotinib) for lung cancer, which were introduced successively in the Netherlands between 2000 and 2012. We apply the technological innovation system (TIS) approach to understand the development, implementation and diffusion of new markets, including new roles for users and producers, new forms of regulation and novel user practices regarding innovative health technologies. We show that market access became institutionalised as part of the technological innovation system of the first-mover personalised medicine, i.e. the market was formed, paving the way for the later personalised medicine products.",

keywords = "Market formation, Institutionalisation, Technological innovation system, Transition, Personalised cancer medicine",

author = "Moors, \{Ellen H.M.\} and \{Kukk Fischer\}, Piret and Boon, \{Wouter P.C.\} and Frank Schellen and Negro, \{Simona O.\}",

year = "2018",

month = mar,

doi = "10.1016/j.techfore.2017.11.011",

language = "English",

volume = "128",

pages = "133--143",

journal = "Technological Forecasting and Social Change",

issn = "0040-1625",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands

AU - Moors, Ellen H.M.

AU - Kukk Fischer, Piret

AU - Boon, Wouter P.C.

AU - Schellen, Frank

AU - Negro, Simona O.

PY - 2018/3

Y1 - 2018/3

N2 - Abstract The article aims to understand the institutionalisation process of markets for innovative products. To pursue this study of market formation, we analysed the introduction of innovative personalised medicines products: Herceptin® (trastuzumab) for breast cancer and Tarceva® (erlotinib) for lung cancer, which were introduced successively in the Netherlands between 2000 and 2012. We apply the technological innovation system (TIS) approach to understand the development, implementation and diffusion of new markets, including new roles for users and producers, new forms of regulation and novel user practices regarding innovative health technologies. We show that market access became institutionalised as part of the technological innovation system of the first-mover personalised medicine, i.e. the market was formed, paving the way for the later personalised medicine products.

AB - Abstract The article aims to understand the institutionalisation process of markets for innovative products. To pursue this study of market formation, we analysed the introduction of innovative personalised medicines products: Herceptin® (trastuzumab) for breast cancer and Tarceva® (erlotinib) for lung cancer, which were introduced successively in the Netherlands between 2000 and 2012. We apply the technological innovation system (TIS) approach to understand the development, implementation and diffusion of new markets, including new roles for users and producers, new forms of regulation and novel user practices regarding innovative health technologies. We show that market access became institutionalised as part of the technological innovation system of the first-mover personalised medicine, i.e. the market was formed, paving the way for the later personalised medicine products.

KW - Market formation

KW - Institutionalisation

KW - Technological innovation system

KW - Transition

KW - Personalised cancer medicine

U2 - 10.1016/j.techfore.2017.11.011

DO - 10.1016/j.techfore.2017.11.011

M3 - Article

SN - 0040-1625

VL - 128

SP - 133

EP - 143

JO - Technological Forecasting and Social Change

JF - Technological Forecasting and Social Change

ER -

Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this